Skip to main content

Intuitive Surgical, Inc. (ISRG) Stock Analysis

Range Bound setup

HoldModerate Confidence

Healthcare · Medical Instruments & Supplies

Hold if already holding. Not a fresh buy at $441.80, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole-sourced and single-sourced suppliers; Expensive valuation.

Intuitive Surgical makes da Vinci robotic surgical systems, Ion endoluminal systems, instruments/accessories, and training/service programs used globally across general, urologic, gynecologic, cardiothoracic, and other surgeries. Revenue comes from system placements (capital),... Read more

$441.80+19.3% A.UpsideScore 5.9/10#6 of 25 Medical Instruments & Supplies
QualityF-score9 / 9FCF yield1.45%
Stop $415.82Target $526.86(analyst − 8%)A.R:R 3.3:1
Analyst target$572.68+29.6%30 analysts
$526.86our TP
$441.80price
$572.68mean
$378
$750

Hold if already holding. Not a fresh buy at $441.80, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole-sourced and single-sourced suppliers; Expensive valuation. Chart setup: RSI 43 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.

Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 63d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.

Val3.2Qual8.1Grw7.0Mom4.0Sent7.5Ins5.0Peer5.9Tech5.9Risk5.95.9OVERALL

Recent Developments — Intuitive Surgical, Inc.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
V7 flight-to-quality bonus: +0.5 (Q=8.1 in RISK_OFF)
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Risks
Concentration risk — Supplier: sole-sourced and single-sourced suppliers
Expensive valuation
Below 200-MA, MA slope -1.8%/30d (confirmed downtrend)

Key Metrics

P/E (TTM)53.5
P/E (Fwd)37.3
Mkt Cap$155.8B
EV/EBITDA39.0
Profit Mgn28.2%
ROE17.2%
Rev Growth23.0%
Beta1.51
DividendNone
Rating analysts41

Quality Signals

Piotroski F9/9MoatNarrow

Options Flow

P/C1.71bearish
IV42%normal

Concentration Risks(10-K Item 1A)

  • HIGHSuppliersole-sourced and single-sourced suppliers
    10-K Item 1A: 'Some of the components necessary for the assembly of our products are currently provided to us by sole-sourced suppliers or single-sourced suppliers due to, among other things, quality considerations'

Material Events(8-K, last 90d)

  • 2026-05-04Item 5.02LOW
    Stockholders approved amendment of 2010 Incentive Award Plan at April 30, 2026 Annual Meeting, increasing reserved shares by 5M to 125.35M total and extending plan term to January 29, 2036.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Ev Ebitda
0.0
Ps
0.2
Pe
2.3
Forward Pe
2.9
Peg Ratio
4.1
Analyst Target
7.5
Forward P/E: 37.3xPEG: 2.36
GatesMomentum 4.0<4.5Death cross (50MA < 200MA)A.R:R 3.3 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 63d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
43 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $417.74Resistance $491.15

Price Targets

$416
$527
A.Upside+19.3%
A.R:R3.3:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Momentum score 4.0/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-07-21 (63d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ISRG stock a buy right now?

Hold if already holding. Not a fresh buy at $441.80, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole-sourced and single-sourced suppliers; Expensive valuation. Chart setup: RSI 43 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $526.86 (+19.3%), stop $415.82 (−6.2%), A.R:R 3.3:1. Score 5.9/10, moderate confidence.

What is the ISRG stock price target?

Take-profit target: $526.86 (+19.3% upside). Target $526.86 (+19.3%), stop $415.82 (−6.2%), A.R:R 3.3:1. Stop-loss: $415.82.

What are the risks of investing in ISRG?

Concentration risk — Supplier: sole-sourced and single-sourced suppliers; Expensive valuation; Below 200-MA, MA slope -1.8%/30d (confirmed downtrend).

Is ISRG overvalued or undervalued?

Intuitive Surgical, Inc. trades at a P/E of 53.5 (forward 37.3). TrendMatrix value score: 3.2/10. Verdict: Hold.

What do analysts say about ISRG?

41 analysts cover ISRG with a consensus score of 4.0/5. Average price target: $573.

What does Intuitive Surgical, Inc. do?Intuitive Surgical makes da Vinci robotic surgical systems, Ion endoluminal systems, instruments/accessories, and...

Intuitive Surgical makes da Vinci robotic surgical systems, Ion endoluminal systems, instruments/accessories, and training/service programs used globally across general, urologic, gynecologic, cardiothoracic, and other surgeries. Revenue comes from system placements (capital), instruments/accessories (recurring), and service contracts; OUS markets were ~32% of 2025 revenue.

Related stocks: RMD (ResMed Inc.) · WST (West Pharmaceutical Services, I) · MDLN (Medline Inc.) · BDX (Becton, Dickinson and Company) · ALC (Alcon Inc.)